Can a daily pill regrow hair in alopecia areata? a trial seeks answers

NCT ID NCT07733765

Not yet recruiting Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether the experimental drug ritlecitinib can safely and effectively regrow hair in people aged 12 and older with moderate alopecia areata, a condition causing patchy hair loss. Participants take a daily capsule for 24 weeks, with some receiving placebo. The study compares hair regrowth between groups to see if ritlecitinib offers a real benefit.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental drug called ritlecitinib
What this could lead to: If it works, ritlecitinib could offer a new treatment option for people with moderate alopecia areata, potentially regrowing significant hair.
What could go wrong: This is a phase 3 trial, but results are not yet known. The drug may not work better than placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALOPECIA AREATA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alopecia areata

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALOPECIA AREATA

Contacts and locations

Locations

Center for Clinical Studies - Houston - Binz Street

Houston, Texas, 77004, United States
Center for Clinical Studies, LTD. LLP

Houston, Texas, 77004, United States
Dawes Fretzin Clinical Research Group, LLC

Indianapolis, Indiana, 46250, United States
University of Iowa Hospitals & Clinics

Iowa City, Iowa, 52242, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.